CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$346.76M, lower than 95% of all stocks globally
- PositionGross margin is 99%, higher than 95% of its Biotechnology peers (median 83.3%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.38BUSDvs all stocks (USD)
Revenue (TTM)
874.09MUSDvs all stocks (USD)
Profit Margin
-64.66%vs Biotechnology peers
Beta
0.4000xvs all stocks
52-Week Change
46.52%vs all stocks
Market Capitalization
10.38BUSDvs all stocks (USD)
Enterprise Value
10.65BUSDvs all stocks (USD)
Forward P/E
-60.28xvs Biotechnology peers
Price to Sales (TTM)
12.09xvs Biotechnology peers
Price to Book (MRQ)
23.94xvs Biotechnology peers
Enterprise to Revenue
12.19xvs Biotechnology peers
Enterprise to EBITDA
-18.38xvs Biotechnology peers
Gross Margin
98.98%vs Biotechnology peers
Profit Margin
-64.66%vs Biotechnology peers
Operating Margin
-38.18%vs Biotechnology peers
Return on Assets (TTM)
-12.43%vs Biotechnology peers
Return on Equity (TTM)
-105.50%vs Biotechnology peers
Revenue (TTM)
874.09MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.36USDUpdated Aug 27, 2026Quarterly Revenue Growth
-40.70%vs Biotechnology peers
Gross Profit (TTM)
-60.60MUSDvs all stocks (USD)
EBITDA (TTM)
-579.48MUSDvs all stocks (USD)
Net Income (TTM)
-565.17MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-496.43MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-346.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
943.71MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
15.91MUSDFY2025 · Dec 31, 2025Gross Profit
927.80MUSDFY2025 · Dec 31, 2025Operating Income
-381.72MUSDvs all stocks (USD)
Pre-tax Income
-379.60MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.79MUSDFY2025 · Dec 31, 2025Net Income
-381.39MUSDFY2025 · Dec 31, 2025EBIT
-295.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-381.11MUSDFY2025 · Dec 31, 2025Research & Development
915.62MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
393.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
83.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.38USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.38USDFY2025 · Dec 31, 2025Basic Shares Outstanding
160.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
160.01MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-381.39MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-300.86MUSDFY2025 · Dec 31, 2025Free Cash Flow
-352.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
372.26MUSDFY2025 · Dec 31, 2025Interest Paid
10.78MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-381.39MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
22.69MUSDFY2025 · Dec 31, 2025Stock-based Compensation
133.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
27.13MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
26.13MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-15.36MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-113.94MUSDFY2025 · Dec 31, 2025Capital Expenditures
-51.44MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-5.64MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.92BUSDFY2025 · Dec 31, 2025Sale of Investments
1.70BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-272.14MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
770.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-267.81MUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-18.95MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
675.84MUSDFY2025 · Dec 31, 2025Shares Outstanding
165.90MSharesUpdated Aug 27, 2026Float Shares
164.85MSharesUpdated Aug 27, 2026Shares Short
20.91MSharesUpdated Aug 27, 2026Short Ratio
7.02daysvs all stocks
Short % of Shares Outstanding
16.66%vs all stocks
% Held by Insiders
0.61%vs all stocks
% Held by Institutions
110.30%vs all stocks
Total Cash (MRQ)
2.10BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.65USDUpdated Aug 27, 2026Total Debt (MRQ)
2.19BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
4.98xvs Biotechnology peers
Current Ratio (MRQ)
7.89xvs Biotechnology peers
Book Value per Share (MRQ)
2.65USDUpdated Aug 27, 2026Total Assets
3.52BUSDvs all stocks (USD)
Total Current Assets
2.99BUSDFY2025 · Dec 31, 2025Total Liabilities
3.03BUSDFY2025 · Dec 31, 2025Total Non-current Assets
533.20MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.25BUSDFY2025 · Dec 31, 2025Total Current Liabilities
781.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
372.26MUSDFY2025 · Dec 31, 2025Other Short-term Investments
2.31BUSDFY2025 · Dec 31, 2025Inventory
10.05MUSDFY2025 · Dec 31, 2025Accounts Payable
28.08MUSDFY2025 · Dec 31, 2025Short-term Debt
454.69MUSDFY2025 · Dec 31, 2025Deferred Revenue
73.76MUSDFY2025 · Dec 31, 2025Long-term Debt
1.61BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
551.35MUSDFY2025 · Dec 31, 2025Common Stock (Book)
163.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.63BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
489.09MUSDvs all stocks (USD)
52-Week Low
42.13USDUpdated Aug 27, 202652-Week High
86.74USDUpdated Aug 27, 202652-Week Change
46.52%vs all stocks
Beta
0.4000xvs all stocks
50-Day MA
63.78USDUpdated Aug 27, 2026200-Day MA
73.94USDUpdated Aug 27, 2026Avg 10-Day Volume
2.24MSharesUpdated Aug 27, 2026Avg 30-Day Volume
2.82MSharesUpdated Aug 27, 2026Diluted EPS (TTM)
-3.57USDUpdated Aug 27, 2026Other Income / Expense
92.13MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 99%, higher than 95% of its Biotechnology peers (median 83.3%)Significant
Gross margin: 0.99Industry median: 0.83Industry P95: 0.98Peers compared: 24.00
Debt-to-equity is 4.98×, higher than 95% of its Biotechnology peers (median 0.24×)Significant
Debt-to-equity: 4.98Industry median: 0.24Industry P95: 4.09Peers compared: 24.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.99Profit Margin: -0.65
Significant cash reserves alongside high leverageNotable
Cash (USD): 2,102,353,024Total Debt (USD): 2,189,019,904Debt-to-Equity: 4.98
Financial Health
Altman Z-Score 1.75: grey zoneSignificant
Altman Z-Score: 1.75
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$346.76M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -346,764,640Global P5: -209,187,555.994
Market cap is $10.38B, above the global median of $1.18BNotable
Market cap (USD): 10,377,379,987Global Median: 1,179,398,897.704
Revenue is $874.09M, above the global median of $534.05MNotable
Revenue (USD): 874,092,992Global Median: 534,052,387.958
Companies that share the same coordination system — how they create, deliver, or capture value.
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Praxis Precision Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lupin Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Krystal Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule